凝血酶激活的纤溶抑制物与反复妊娠丢失关系的研究进展  

Advances on the relationship between thrombin-activatable fibrinolysis inhibitor(TAFI) and recurrent pregnancy loss

作　　者：易小芳[1] 谭超[1] 

机构地区：[1]三峡大学第一临床医学院检验科,宜昌443002

出　　处：《天津医药》2015年第3期327-329,共3页Tianjin Medical Journal

基　　金：湖北省自然科学基金(2014CFB307)

摘　　要：反复妊娠丢失(recurrent pregnancy loss,RPL)是常见于妊娠期的一种并发症,影响着2%的育龄妇女。最新研究发现高水平凝血酶激活的纤溶抑制物(thrombin-activatable fibrinolysis inhibitor,TAFI)可降低早期RPL发生的风险。TAFI是一种羧肽酶原,激活成活化型TAFI(TAFIa)后,能够使纤溶酶失去与纤维蛋白的作用位点而发挥纤溶抑制及调节血栓形成的作用。而纤溶系统的损坏是妊娠期妇女发生RPL的危险因素之一,关于TAFI与RPL的研究目前已经成为国内外医学界的研究热点之一。本文结合有关文献就TAFI近年来研究现状及与RPL的关系进行综述,旨在为临床治疗和预防RPL寻找新的方法和线索。Recurrent pregnancy loss （RPL） is a common complication of pregnancy, which affects 2% fertile women. A recent research has found that high level of thrombin-activatable fibrinolysis inhibitor （TAFI） can reduce the occurrence risk of early RPL. TAFI is one kind of carboxypeptidase, which can be activated as TAFIa. TAFIa can make the fibrinolysin lose its working site, which can interact with the fibrin to play a role in the regulation of fibrinolysis and the inhibition of throm-bus formation. The damage of fibrinolytic system is one of the risk factors for the occurrence of RPL in pregnant women, which has become one of the hotspots in the medical profession. In this paper, recent literature on TAFI and its relationship with recurrent pregnancy loss has been reviewed, hoping for new ways and clues in clinical treatment and prevention of RPL.

关 键 词：凝血酶 纤溶酶原灭活剂 流产 习惯性 综述 凝血酶激活的纤溶抑制物 

分 类 号：R714.2[医药卫生—妇产科学]